iwCLL 2017 | What to look for in novel CLL therapies

Kostas Stamatopoulos

Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses what is important when evaluating new therapies. Duration of response to treatment and patient quality of life are two major factors when considering new therapies and managing disease. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video